Quantum Private Wealth LLC Has $4.35 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Quantum Private Wealth LLC boosted its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 0.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 58,764 shares of the medical research company’s stock after buying an additional 400 shares during the quarter. Exact Sciences accounts for approximately 1.8% of Quantum Private Wealth LLC’s investment portfolio, making the stock its 9th largest position. Quantum Private Wealth LLC’s holdings in Exact Sciences were worth $4,347,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Exact Sciences by 4.4% in the 3rd quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company’s stock valued at $541,823,000 after purchasing an additional 698,740 shares during the period. Capital World Investors boosted its position in shares of Exact Sciences by 17.2% in the 1st quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock valued at $383,652,000 after purchasing an additional 804,159 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Exact Sciences by 11.8% in the 3rd quarter. Artisan Partners Limited Partnership now owns 3,961,514 shares of the medical research company’s stock valued at $270,254,000 after purchasing an additional 418,770 shares during the period. Geode Capital Management LLC boosted its position in shares of Exact Sciences by 3.7% in the 1st quarter. Geode Capital Management LLC now owns 2,591,057 shares of the medical research company’s stock valued at $175,458,000 after purchasing an additional 91,883 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Exact Sciences by 11.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,858,380 shares of the medical research company’s stock valued at $137,483,000 after purchasing an additional 192,372 shares during the period. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Performance

Shares of EXAS stock traded down $0.01 during trading on Wednesday, reaching $63.85. The company had a trading volume of 1,093,091 shares, compared to its average volume of 2,305,947. The firm’s 50 day simple moving average is $63.32 and its two-hundred day simple moving average is $65.13. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07. Exact Sciences Co. has a one year low of $56.05 and a one year high of $100.77. The company has a market capitalization of $11.59 billion, a PE ratio of -57.12 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.26. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. The business had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. During the same period last year, the business earned ($0.72) EPS. The firm’s revenue was up 17.0% compared to the same quarter last year. Sell-side analysts forecast that Exact Sciences Co. will post -0.86 earnings per share for the current year.

Insider Activity at Exact Sciences

In related news, Director D Scott Coward sold 1,376 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $84,527.68. Following the sale, the director now owns 41,580 shares of the company’s stock, valued at approximately $2,554,259.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Exact Sciences news, Director D Scott Coward sold 1,376 shares of Exact Sciences stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $84,527.68. Following the completion of the transaction, the director now owns 41,580 shares in the company, valued at approximately $2,554,259.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Jacob A. Orville sold 1,879 shares of Exact Sciences stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $56.89, for a total value of $106,896.31. Following the completion of the transaction, the insider now owns 11,754 shares of the company’s stock, valued at approximately $668,685.06. The disclosure for this sale can be found here. Insiders have sold a total of 69,113 shares of company stock valued at $4,165,273 in the last 90 days. 1.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on EXAS shares. Canaccord Genuity Group decreased their price target on Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. William Blair restated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Citigroup restated a “buy” rating and set a $100.00 price objective on shares of Exact Sciences in a research report on Wednesday, April 3rd. Benchmark upgraded Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price objective for the company in a research report on Tuesday, January 2nd. Finally, TheStreet lowered Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Exact Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.44.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.